Rami Abou Jamra

University Hospital Leipzig
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

CUL1 encodes a scaffolding protein of the SKP1-CUL1-F-box E3 ubiquitin ligase complex, which mediates substrate ubiquitination and proteasomal degradation. Despite CUL1’s essential roles, it has not been implicated in human disease. We identified ten unrelated individuals with a syndromic neurodevelopmental disorder, with or without movement abnormalities carrying de novo heterozygous CUL1 variants. Patient-derived iPSCs with p.Lys515Glu exhibited elevated cyclin E level, a CUL1 target. Co-transfection with CUL1 and ubiquitin demonstrated that truncating variants (p.Arg565* and p.Gly512Trpfs*51) impaired polyubiquitin chain formation on β-catenin, supporting a dominant-negative mechanism. In vivo , neural-specific knockdown of Cul1 in Drosophila reduced survival and motor function, while enhancing sensory dendrite regeneration. These phenotypes were differentially rescued by human CUL1 wild-type (WT), p.Leu671Val or truncating variants. WT CUL1 or p.Leu671Val failed to rescue the impaired social interaction in Cul1 knockdown flies, whereas the two truncating variants exacerbated the deficit. Overexpression of p.Arg565* and p.Gly512Trpfs*51 in WT flies recapitulated dendrite regeneration and social deficits, confirming their dominant-negative effects. Their overexpression also caused Akt overactivation, previously shown to be a Cul1 substrate and promote dendrite regeneration, implicating Akt as a downstream effector. These findings establish CUL1 as a novel neurodevelopmental disorder gene and suggest that dominant-negative mechanisms underlie its pathogenesis.

Year:

2025

Parents of children with genetic disorders due to de novo variants are counselled on a recurrence risk estimate of 1-5% for further affected siblings, while the actual probability varies between 0 and 50%. This discrepancy is well known, but barely investigated. We enrolled 135 families, in which a child had been previously identified with a pathogenic seemingly de novo variant (in 140 genes). Covering two germ layers, we collected blood (n=269), buccal (n=223) and nail samples (n=223) of both parents and paternal semen (n=88). Using Nanopore long read sequencing, variants were phased to the parental allele of origin. We performed deep sequencing with unique molecular identifiers of all samples. We investigated for low mosaicism with plotting identified allele fractions and Bayesian analyses. We confirmed the results individually using amplicon-based, spiked-in deep sequencing. Phasing revealed 22% of variants have occurred on the maternal and 78% on the paternal allele. Median raw target read depth achieved >7,000x, reduced to 523x after collapsing across all tissues (n≈130,000 measured values). We identified mosaicism in either the mother (n=2) or the father (n=4): four of them as mixed mosaicism, two cases as paternal gonadal mosaicism. The alternative allele fraction varied from 1.1% to 23%, while the results of the Bayesian model correlated well with amplicon-based sequencing. With 4.4%, we observe a slightly lower number of parental mosaicism compared to the literature. We now apply the amplicon-based sequencing of tissue samples – including semen – to routine counselling of parents with an affected child for individual risk assessment.

Year:

2025

Purpose With exome sequencing now standard, diagnostic labs are in need of a, in principle, to-the-day-accurate list of genes associated with rare diseases. Manual curation efforts are slow and often disease specific, while efforts relying on single sources are too inaccurate and may result in false-positive or false-negative genes. Methods We established the MorbidGenes panel based on a list of publicly available databases: OMIM, PanelApp, SysNDD, ClinVar, HGMD and GenCC. A simple logic allows inclusion of genes that are supported by at least one of these sources, providing a list of all genes with diagnostic relevance. Results The panel is freely available at https://morbidgenes.uni-leipzig.de and currently includes 4960 genes (as of March 2024) with minimally sufficient evidence on disease causality to classify them as diagnostically relevant. Conclusion The MorbidGenes panel is an open and comprehensive overview of diagnostically relevant rare disease genes based on a diverse set of resources. The panel is updated monthly to keep up with the ever increasing number of rare disease genes.

Year:

2024

Hyperpolarization activated Cyclic Nucleotide (HCN) gated channels are crucial for various neurophysiological functions, including learning and sensory functions, and their dysfunction are responsible for brain disorders, such as epilepsy. To date, HCN2 variants have only been associated with mild epilepsy and recently, one monoallelic missense variant has been linked to developmental and epileptic encephalopathy. Here, we expand the phenotypic spectrum of HCN2- related disorders by describing twenty-one additional individuals from fifteen unrelated families carrying HCN2 variants. Seventeen individuals had developmental delay/intellectual disability (DD/ID), two had borderline DD/ID, and one had borderline DD. Ten individuals had epilepsy with DD/ID, with median age of onset of 10 months, and one had epilepsy with normal development. Molecular diagnosis identified thirteen different pathogenic HCN2 variants, including eleven missense variants affecting highly conserved amino acids, one frameshift variant, and one in-frame deletion. Seven variants were monoallelic of which five occurred de novo, one was not maternally inherited, one was inherited from a father with mild learning disabilities, and one was of unknown inheritance. The remaining six variants were biallelic, with four homozygous and two compound heterozygous variants. Functional studies using two-electrode voltage-clamp recordings in Xenopus laevis oocytes were performed on three monoallelic variants, p.(Arg324His), p.(Ala363Val), and p.(Met374Leu), and three biallelic variants, p.(Leu377His), p.(Pro493Leu) and p.(Gly587Asp). The p.(Arg324His) variant induced a strong increase of HCN2 conductance, while p.(Ala363Val) and p.(Met374Leu) displayed dominant negative effects, leading to a partial loss of HCN2 channel function. By confocal imaging, we found that the p.(Leu377His), p.(Pro493Leu) and p.(Gly587Asp) pathogenic variants impaired membrane trafficking, resulting in a complete loss of HCN2 elicited currents in Xenopus oocytes. Structural 3D-analysis in depolarized and hyperpolarized states of HCN2 channels, revealed that the pathogenic variants p.(His205Gln), p.(Ser409Leu), p.(Arg324Cys), p.(Asn369Ser) and p.(Gly460Asp) modify molecular interactions altering HCN2 function. Taken together, our data broadens the clinical spectrum associated with HCN2 variants, and disclose that HCN2 is involved in developmental encephalopathy with or without epilepsy.

Year:

2024

Background We previously described the KINSSHIP syndrome, an autosomal dominant disorder associated with intellectual disability (ID), mesomelic dysplasia and horseshoe kidney,caused by de novo variants in the degron of AFF3. Mouse knock-ins and overexpression in zebrafish provided evidence for a dominant-negative (DN) mode-of-action, wherein an increased level of AFF3 resulted in pathological effects. Methods Evolutionary constraints suggest that other mode-of-inheritance could be at play. We challenged this hypothesis by screening ID cohorts for individuals with predicted-to-be deleterious variants in AFF3 . We used both animal and cellular models to assess the deleteriousness of the identified variants. Results We identified an individual with a KINSSHIP-like phenotype carrying a de novo partial duplication of AFF3 further strengthening the hypothesis that an increased level of AFF3 is pathological. We also detected seventeen individuals displaying a milder syndrome with either heterozygous LoF or biallelic missense variants in AFF3 . Consistent with semi-dominance, we discovered three patients with homozygous LoF and one compound heterozygote for a LoF and a missense variant, who presented more severe phenotypes than their heterozygous parents. Matching zebrafish knockdowns exhibit neurological defects that could be rescued by expressing human AFF3 mRNA, confirming their association with the ablation of aff3 . Conversely, some of the human AFF3 mRNAs carrying missense variants identified in affected individuals did not complement. Overexpression of mutated AFF3 mRNAs in zebrafish embryos produced a significant increase of abnormal larvae compared to wild-type overexpression further demonstrating deleteriousness. To further assess the effect of AFF3 variation, we profiled the transcriptome of fibroblasts from affected individuals and engineered isogenic cells harboring +/+, DN/DN, LoF/+, LoF/LoF or DN/LoF AFF3 genotypes. The expression of more than a third of the AFF3 bound loci is modified in either the DN/DN or the LoF/LoF lines. While the same pathways are affected, only about one-third of the differentially expressed genes are common to these homozygote datasets, indicating that AFF3 LoF and DN variants largely modulate transcriptomes differently, e.g. the DNA repair pathway displayed opposite modulation. Conclusions Our results and the high pleiotropy shown by variation at this locus suggest that minute changes in AFF3 function are deleterious.

Year:

2024

Neurodevelopmental proteasomopathies represent a distinctive category of neurodevelopmental disorders (NDD) characterized by genetic variations within the 26S proteasome, a protein complex governing eukaryotic cellular protein homeostasis. In our comprehensive study, we identified 23 unique variants in PSMC5 , which encodes the AAA-ATPase proteasome subunit PSMC5/Rpt6, causing syndromic NDD in 38 unrelated individuals. Overexpression of PSMC5 variants altered human hippocampal neuron morphology, while PSMC5 knockdown led to impaired reversal learning in flies and loss of excitatory synapses in rat hippocampal neurons. PSMC5 loss-of-function resulted in abnormal protein aggregation, profoundly impacting innate immune signaling, mitophagy rates, and lipid metabolism in affected individuals. Importantly, targeting key components of the integrated stress response, such as PKR and GCN2 kinases, ameliorated immune dysregulations in cells from affected individuals. These findings significantly advance our understanding of the molecular mechanisms underlying neurodevelopmental proteasomopathies, provide links to research in neurodegenerative diseases, and open up potential therapeutic avenues.

Year:

2024

Routine diagnostics is biased towards genes and variants with satisfactory evidence, but rare disorders with only little confirmation of their pathogenicity might be missed. Many of these genes can, however, be considered relevant, although they may have less evidence because they lack OMIM entries or comprise only a small number of publicly available variants from one or a few studies. Here, we present 89 individuals harbouring variants in 77 genes for which only a small amount of public evidence on their clinical significance is available but which we still found to be relevant enough to be reported in routine diagnostics. For 21 genes, we present case reports that confirm the lack or provisionality of OMIM associations (ATP6V0A1, CNTN2, GABRD, NCKAP1, RHEB, TCF7L2), broaden the phenotypic spectrum (CC2D1A, KCTD17, YAP1) or substantially strengthen the confirmation of genes with limited evidence in the medical literature (ADARB1, AP2M1, BCKDK, BCORL1, CARS2, FBXO38, GABRB1, KAT8, PRKD1, RAB11B, RUSC2, ZNF142). Routine diagnostics can provide valuable information on disease associations and support for genes without requiring tremendous research efforts. Thus, our results validate and delineate gene–disorder associations with the aim of motivating clinicians and scientists in diagnostic departments to provide additional evidence via publicly available databases or by publishing short case reports.

Year:

2022

Collaborators (59)

Ype Elgersma

Full professor

Erasmus MC

NETHERLANDS
View details

Sonja Wegscheider

Leipzig University

GERMANY
View details

Tamar Harel

-

ISRAEL
View details

Geeske van Woerden

Associate professor

Erasmus University Rotterdam

NETHERLANDS
View details

Rikke S. Møller

University of Southern Denmark

DENMARK
View details

Rebecca Ganetzky

Associate Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Ian Forster

Senior Principal Research Fellow

Florey Institute of Neuroscience and Mental Health

AUSTRALIA
View details

Nicolas GUEX

Head, Bioinformatics Competence Center

University of Lausanne

SWITZERLAND
View details

EFTERPI PAVLIDOU

Assistant Professor of Pediatrics

University of Ioannina

GREECE
View details

Lisenka Vissers

Radboud University Medical Center

NETHERLANDS
View details

Patrick Van Bogaert

Université d'Angers

FRANCE
View details

Peter Krawitz

University of Bonn

GERMANY
View details

Reza Maroofian

-

UNITED KINGDOM
View details

Yuanquan Song

Children's Hospital of Philadelphia

UNITED STATES
View details

Dominique Bonneau

Professor of Medical Genetics

Université d'Angers

FRANCE
View details

Sissy Bassani

University of Zurich

SWITZERLAND
View details

Henry Houlden

Professor of Neurogenetics

-

UNITED KINGDOM
View details

Arnaud Droit

Professor

Université Laval Faculté de médecine

CANADA
View details

Alfredo Brusco

Full Professor in Medical Genetics

Università degli Studi di Torino

ITALY
View details

Tzung-Chien Hsieh

University Hospital Bonn

GERMANY
View details

Christian Iseli

Head of Bioinformatics Competence Center

École Polytechnique Fédérale de Lausanne

SWITZERLAND
View details

Evan Eichler

Howard Hughes Medical Institute

UNITED STATES
View details

Florence Petit

Université de Lille

FRANCE
View details

Hakon Hakonarson

Professor and Director

Children's Hospital of Philadelphia

UNITED STATES
View details

Marie-Pierre Bousquet

Institute of Pharmacology and Structural Biology

FRANCE
View details

Peter Werner Hildebrand

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY
View details

Stéphane Bézieau

Université de Nantes

FRANCE
View details

Andrew Dauber

The George Washington University School of Medicine and Health SCiences

UNITED STATES
View details

Giovanna Ambrosini

Senior Scientist

EPFL (École Polytechnique Fédérale de Lausanne)

SWITZERLAND
View details

Frederic Laumonnier

Team Leader, Research Director

INSERM

FRANCE
View details

Dmitriy Niyazov

Associate Professor

Duke University

UNITED STATES
View details

Renske Oegema

UMC Utrecht

NETHERLANDS
View details

Christian Gilissen

Professor of Genome Bioinformatics

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Christian LEGROS

Director - Professor in Neurosciences

Université d'Angers

FRANCE
View details

Jens Meiler

Vanderbilt University

UNITED STATES
View details

Kimberly McDonald

Assistant Professor

University of Mississippi Medical Center

UNITED STATES
View details

Marni Falk

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Robin-Tobias Jauss

Staff Scientist

University Hospital Leipzig

GERMANY
View details

Elke Hammer

University Medicine Greifswald

GERMANY
View details

Rolf Stottmann

Professor

Ohio State University

UNITED STATES
View details

Marcello Scala

Researcher

University of Genoa

ITALY
View details

Konrad Platzer

University Hospital Leipzig

GERMANY
View details

Elke Krueger

Director

University Medicine Greifswald

GERMANY
View details

James R. Lupski

-

UNITED STATES
View details

Tychele Turner

Assistant Professor

Washington University School of Medicine

UNITED STATES
View details

Bernt Popp

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY
View details

Frédéric Ebstein

Group Leader

Université de Nantes

FRANCE
View details

Alexandre Reymond

University of Lausanne

SWITZERLAND
View details

Steffen Syrbe

Director ad Interim Clinic 5, Full Professor, Consultant Neuropediatrics and Pediatrics, Head of Division for Pediatric Epileptology

Heidelberg University

GERMANY
View details

Andreas Grabrucker

Lecturer (Assist. Prof)

University of Limerick

IRELAND
View details

Gregory Costain

Hospital for Sick Children

CANADA
View details

Antonio Vitobello

Full professor

Université de Bourgogne

FRANCE
View details

Anita Rauch

University of Zurich

SWITZERLAND
View details

Thomas Smol

PU-PH

Université de Lille

FRANCE
View details

Christopher Reid

University of Melbourne

AUSTRALIA
View details

Julien Marcoux

CNRS Research Director

Institute of Pharmacology and Structural Biology

FRANCE
View details

Dong Li

University of Pennsylvania

UNITED STATES
View details

Anne O'Donnell-Luria

Associate Professor

Boston Children's Hospital

UNITED STATES
View details

Miroslava Hancarova

Charles University

CZECH REPUBLIC
View details